ID H0385

Pharmaceutical manufacturers are prohibited from denying, restricting, or interfering with the acquisition or delivery of 340B drugs to contract pharmacies on behalf of covered entities participating in the federal 340B drug pricing program.

Manufacturers cannot interfere with or restrict pharmacy contracts between covered entities and contract pharmacies.

Manufacturers are barred from requiring covered entities or contract pharmacies to submit claims, utilization, purchasing, or other data as a condition for 340B drug access, though compliance audits under HHS procedures are still permitted.

The law becomes null and void if the federal 340B drug pricing program (42 CFR 10) is eliminated at the federal level.

Declared an emergency measure with an effective date of July 1, 2025.